Ebola vaccines from GlaxoSmithKline and Merck elicited antibody responses that lasted one year after vaccination, according to new research.

Young biotech Codagenix just secured $3 million in funding to advance its live-attenuated RSV vaccine candidate.

Sanofi will invest more than $200 million in a new plant in France to produce its newest flu vaccine, VaxigripTetra.

Affluent regions with more new moms are most likely to be spawning grounds for antivaccine tweets, a five-year study found.

Here is some other vaccine news of note for this week.

A large-scale phase 3 study shows that Merck's Gardasil 9 vaccine protects against HPV-related cancers for at least six years.

Here is some other vaccine news of note for this week.

As it works toward its goal of eventually licensing a low-cost pneumonia vaccine, PnuVax will have a sum of money to lean on.

Researchers in England are kicking off the world's first large human trial of a "universal" influenza shot.

The U.S. government is committing millions of dollars in support for leading Ebola vaccine programs at Merck and Johnson & Johnson.